Format

Send to

Choose Destination
Alzheimers Res Ther. 2015 Oct 5;7(1):63. doi: 10.1186/s13195-015-0145-y.

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients.

Author information

1
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Wallenberg Laboratory, floor 2, Inga-Marie Nilssons gata 53, 205 02, Malmö, Sweden. malin.wennstrom@med.lu.se.
2
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Wallenberg Laboratory, floor 2, Inga-Marie Nilssons gata 53, 205 02, Malmö, Sweden. sara.hall@med.lu.se.
3
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Wallenberg Laboratory, floor 2, Inga-Marie Nilssons gata 53, 205 02, Malmö, Sweden. Katarina.Nagga@skane.se.
4
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Wallenberg Laboratory, floor 2, Inga-Marie Nilssons gata 53, 205 02, Malmö, Sweden. Elisabet.Londos@skane.se.
5
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Wallenberg Laboratory, floor 2, Inga-Marie Nilssons gata 53, 205 02, Malmö, Sweden. Lennart.Minthon@skane.se.
6
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Wallenberg Laboratory, floor 2, Inga-Marie Nilssons gata 53, 205 02, Malmö, Sweden. oskar.hansson@med.lu.se.

Abstract

INTRODUCTION:

Inflammatory processes have previously been shown to influence cognition and progression of dementia. An involvement of interleukin (IL)-6 has in particular been suggested as altered levels of IL-6 in cerebrospinal fluid (CSF) have been found in patients with Alzheimer's disease (AD). Also, an association between cognitive decline and levels of IL-6 in CSF have been reported. The aim of the present study was to investigate whether patients clinically diagnosed with dementia with Lewy bodies (DLB) display altered CSF IL-6 levels in comparison with patients with AD and control subjects without dementia and whether the IL-6 levels are correlated with cognitive status and biomarkers for AD and synucleinopathy.

METHODS:

To analyse CSF of patients with AD (n = 45), patients with DLB (n = 29) and control subjects without dementia (n = 36), we used immunoassays to measure levels of IL-6 (multiplex electrochemiluminescence); AD markers phosphorylated tau, total tau and amyloid-β1-42 (enzyme-linked immunosorbent assay [ELISA]); and α-synuclein (ELISA). Cognitive status was evaluated using the Mini Mental State Examination (MMSE).

RESULTS:

Our analysis showed significantly lower levels of IL-6 in CSF from patients with DLB than in CSF from patients with AD and control subjects without dementia. The IL-6 levels were also negatively correlated with MMSE and positively correlated with α-synuclein CSF levels.

CONCLUSIONS:

Our findings support previous studies by demonstrating a link between inflammatory processes and dementia progression and further strengthen the hypothesis that IL-6 is involved in dementia pathology and cognitive decline.

PMID:
26434635
PMCID:
PMC4593189
DOI:
10.1186/s13195-015-0145-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center